AR106486A1 - Antagonistas de receptores de cgrp - Google Patents
Antagonistas de receptores de cgrpInfo
- Publication number
- AR106486A1 AR106486A1 ARP160103293A ARP160103293A AR106486A1 AR 106486 A1 AR106486 A1 AR 106486A1 AR P160103293 A ARP160103293 A AR P160103293A AR P160103293 A ARP160103293 A AR P160103293A AR 106486 A1 AR106486 A1 AR 106486A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclic ring
- cgrp
- receiver antagonists
- optionally substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1519196.8A GB201519196D0 (en) | 2015-10-30 | 2015-10-30 | CGRP Receptor Antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106486A1 true AR106486A1 (es) | 2018-01-17 |
Family
ID=55130448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103293A AR106486A1 (es) | 2015-10-30 | 2016-10-28 | Antagonistas de receptores de cgrp |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9808457B2 (https=) |
| EP (1) | EP3368525B1 (https=) |
| JP (1) | JP6877451B2 (https=) |
| CN (1) | CN108473465B (https=) |
| AR (1) | AR106486A1 (https=) |
| AU (1) | AU2016347521C1 (https=) |
| BR (1) | BR112018008423B1 (https=) |
| CA (1) | CA3002621C (https=) |
| ES (1) | ES2719573T3 (https=) |
| GB (1) | GB201519196D0 (https=) |
| IL (1) | IL258892B (https=) |
| SG (1) | SG11201803379WA (https=) |
| TW (1) | TWI722035B (https=) |
| WO (1) | WO2017072721A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| WO2018178938A1 (en) * | 2017-03-31 | 2018-10-04 | Heptares Therapeutics Limited | Cgrp receptor antagonists |
| MX2020009856A (es) | 2018-03-25 | 2020-10-08 | Biohaven Pharm Holding Co Ltd | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). |
| US20210361774A1 (en) | 2018-10-16 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
| CN112969696B (zh) | 2018-11-02 | 2024-06-11 | 达纳-法伯癌症研究公司 | 乙酰化书写器抑制剂的开发及其用途 |
| GB201908430D0 (en) | 2019-06-12 | 2019-07-24 | Heptares Therapeutics Ltd | Cgrp antagonist compounds |
| GB201908420D0 (en) * | 2019-06-12 | 2019-07-24 | Heptares Therapeutics Ltd | Cgrp antagonist compounds |
| WO2021141662A1 (en) | 2020-01-10 | 2021-07-15 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
| MX2022011725A (es) * | 2020-03-23 | 2022-10-10 | Biohaven Pharm Holding Co Ltd | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. |
| WO2023034466A1 (en) * | 2021-09-02 | 2023-03-09 | Pfizer Ireland Pharmaceuticals | Cgrp antagonists for treating psoriasis |
| CN116023391B (zh) * | 2022-12-13 | 2024-09-06 | 药康众拓(江苏)医药科技有限公司 | 一类氘代哌啶酰胺类cgrp抑制剂药物及用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2732221B1 (fr) | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
| SK285631B6 (sk) | 1996-09-10 | 2007-05-03 | Dr. Karl Thomae Gmbh | Modifikované aminokyseliny, farmaceutický prostriedok s ich obsahom a ich použitie |
| US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| WO1999064002A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| DE10206770A1 (de) | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096 |
| RS52552B (sr) | 2002-06-05 | 2013-04-30 | Bristol-Myers Squibb Company | Antagonisti, peptidnog receptora koji je u vezi sa kalcitoninskim genom |
| US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| DE10250082A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| RS20060382A (sr) | 2003-12-05 | 2008-09-29 | Bristol-Myers Squibb Company, | Antagonisti receptora za peptid povezan sa genom za kalcitonin |
| TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
| DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| DE102004018795A1 (de) * | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US20050233980A1 (en) | 2004-04-20 | 2005-10-20 | Boehringer Ingelheim International Gmbh | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine |
| DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| BRPI0517418A (pt) | 2004-10-13 | 2008-10-07 | Merck & Co Inc | composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça |
| WO2006044449A2 (en) | 2004-10-14 | 2006-04-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
| DE602005027230D1 (de) | 2004-10-22 | 2011-05-12 | Merck Sharp & Dohme | Cgrp-rezeptorantagonisten |
| EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7834007B2 (en) * | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| KR20090021214A (ko) | 2006-06-08 | 2009-02-27 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｇｒｐ-길항제에 의한 위장 장애의 치료 |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8481546B2 (en) * | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
-
2015
- 2015-10-30 GB GBGB1519196.8A patent/GB201519196D0/en not_active Ceased
-
2016
- 2016-10-28 CA CA3002621A patent/CA3002621C/en active Active
- 2016-10-28 TW TW105135022A patent/TWI722035B/zh active
- 2016-10-28 WO PCT/IB2016/056517 patent/WO2017072721A1/en not_active Ceased
- 2016-10-28 EP EP16791443.1A patent/EP3368525B1/en active Active
- 2016-10-28 JP JP2018541591A patent/JP6877451B2/ja active Active
- 2016-10-28 AR ARP160103293A patent/AR106486A1/es active IP Right Grant
- 2016-10-28 BR BR112018008423-9A patent/BR112018008423B1/pt active IP Right Grant
- 2016-10-28 AU AU2016347521A patent/AU2016347521C1/en active Active
- 2016-10-28 ES ES16791443T patent/ES2719573T3/es active Active
- 2016-10-28 CN CN201680063967.1A patent/CN108473465B/zh active Active
- 2016-10-28 SG SG11201803379WA patent/SG11201803379WA/en unknown
- 2016-10-28 US US15/336,866 patent/US9808457B2/en active Active
-
2017
- 2017-09-25 US US15/713,775 patent/US10300056B2/en active Active
-
2018
- 2018-04-24 IL IL258892A patent/IL258892B/en active IP Right Grant
-
2019
- 2019-04-08 US US16/377,519 patent/US10888561B2/en active Active
-
2020
- 2020-12-31 US US17/139,299 patent/US12178813B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL258892B (en) | 2020-07-30 |
| US20210213011A1 (en) | 2021-07-15 |
| ES2719573T3 (es) | 2019-07-11 |
| SG11201803379WA (en) | 2018-05-30 |
| WO2017072721A1 (en) | 2017-05-04 |
| JP2018532788A (ja) | 2018-11-08 |
| EP3368525A1 (en) | 2018-09-05 |
| US10888561B2 (en) | 2021-01-12 |
| CA3002621A1 (en) | 2017-05-04 |
| US9808457B2 (en) | 2017-11-07 |
| US20180015085A1 (en) | 2018-01-18 |
| US20170121348A1 (en) | 2017-05-04 |
| EP3368525B1 (en) | 2019-03-13 |
| AU2016347521B2 (en) | 2020-09-17 |
| BR112018008423A2 (pt) | 2018-11-06 |
| CN108473465B (zh) | 2021-03-02 |
| TWI722035B (zh) | 2021-03-21 |
| US12178813B2 (en) | 2024-12-31 |
| GB201519196D0 (en) | 2015-12-16 |
| IL258892A (en) | 2018-06-28 |
| US20190231773A1 (en) | 2019-08-01 |
| TW201722935A (zh) | 2017-07-01 |
| CN108473465A (zh) | 2018-08-31 |
| CA3002621C (en) | 2024-01-23 |
| US10300056B2 (en) | 2019-05-28 |
| BR112018008423B1 (pt) | 2024-02-15 |
| JP6877451B2 (ja) | 2021-05-26 |
| AU2016347521A1 (en) | 2018-05-17 |
| AU2016347521C1 (en) | 2021-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106486A1 (es) | Antagonistas de receptores de cgrp | |
| EP3621624A4 (en) | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | |
| AR099400A1 (es) | Compuesto heterocíclico fusionado | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| CR20170099A (es) | Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas | |
| AR094342A1 (es) | Derivados de ácido borónico útiles como agentes antimicrobianos | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 | |
| AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| EA201600248A1 (ru) | Антибактериальные производные 2h-индазола | |
| AR101255A1 (es) | Derivados de isoindolinona | |
| AR095523A1 (es) | Derivados piridin-4-ilo | |
| AR097932A1 (es) | Antagonista del receptor de somatostatina del subtipo 5 (sstr5) | |
| AR111414A1 (es) | Derivados de heteroarilcarboxamida como inhibidores de la calicreína plasmática | |
| MA44781B1 (fr) | Composé hétérocyclique condensé | |
| AR097252A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| DOP2018000042A (es) | Antagonistas del receptor de cgrp | |
| CR20160082A (es) | Nuevo derivado de triazina | |
| AR110119A1 (es) | Proceso para la purificación de pirazolpiridazinas | |
| AR104899A1 (es) | Compuestos reguladores del crecimiento vegetal | |
| EP3383869A4 (en) | ARYLSULFONAMIDES AS BLT1 ANTAGONISTS | |
| EP3383868A4 (en) | ARYLSULFONAMIDES AS BLT1 ANTAGONISTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |